Last reviewed · How we verify
Ketamine-assisted psychotherapy
Ketamine-assisted psychotherapy is a Small molecule drug developed by Juliana Zambrano, MD, MPH. It is currently in Phase 2 development.
At a glance
| Generic name | Ketamine-assisted psychotherapy |
|---|---|
| Sponsor | Juliana Zambrano, MD, MPH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) (EARLY_PHASE1)
- Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. (PHASE2, PHASE3)
- ACT_for Alcohol Use Disorder and Depression (NA)
- Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement (PHASE2)
- Esketamine With or Without Integration Therapy for Treatment-Resistant Depression (PHASE4)
- Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression (PHASE2)
- Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) (PHASE1, PHASE2)
- Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine-assisted psychotherapy CI brief — competitive landscape report
- Ketamine-assisted psychotherapy updates RSS · CI watch RSS
- Juliana Zambrano, MD, MPH portfolio CI
Frequently asked questions about Ketamine-assisted psychotherapy
What is Ketamine-assisted psychotherapy?
Ketamine-assisted psychotherapy is a Small molecule drug developed by Juliana Zambrano, MD, MPH.
Who makes Ketamine-assisted psychotherapy?
Ketamine-assisted psychotherapy is developed by Juliana Zambrano, MD, MPH (see full Juliana Zambrano, MD, MPH pipeline at /company/juliana-zambrano-md-mph).
What development phase is Ketamine-assisted psychotherapy in?
Ketamine-assisted psychotherapy is in Phase 2.